Trump’s FDA Uses AI to Speed Up Product Reviews in Six Minutes

---

Full Story

The FDA, under President Trump, has implemented artificial intelligence to assist in scientific product reviews, reducing days-long processes to just six minutes. FDA Commissioner Makary aims to expand AI use agency-wide by July 1, targeting faster cures for diseases like ALS and cancer. This breakthrough aligns with Trump’s push for government efficiency, promising transformative health advancements.

AI reviewed a product in six minutes, per FDA Commissioner Makary. Traditional reviews often took days, delaying critical treatments.

MEDIA REPORTING

See how news sources on all sides are covering this story.

Left 32% | Right 36% | Center 27% | Unrated 5%

The Context

Makary highlighted AI’s potential for ALS, cancer, and diabetes therapies. The FDA aims to maintain rigorous safety standards despite speed.

Trump’s administration prioritizes streamlining government via technology. The Department of Government Efficiency, led by Elon Musk, supports such reforms.

The U.S. leads globally in medical innovation, with the FDA setting standards. AI adoption could accelerate drug and device approvals.

Some praise AI for faster access to life-saving treatments. Others worry about risks of reduced human oversight in complex reviews.

Makary set a July 1 target for agency-wide AI implementation. This aggressive timeline reflects Trump’s directive to prioritize cures.

Medical reviews require balancing speed, safety, and accuracy. AI’s role sparks debate over technology’s limits in healthcare regulation.